Clinical solutions

Automates breast cancer grading from H&E-stained whole-slide images (WSI), accurately identifying invasive carcinoma and ductal carcinoma in situ (DCIS). It objectively scores mitotic count, tubular formation, and nuclear pleomorphism, addressing key challenges of manual grading such as variability and time constraints, consistent with the Nottingham Grading System. 

Clinical performance highlights

• Substantially reduces grading time (50% faster)
• High correlation with expert grading assessments
• Consistently reproducible, reducing interobserver variability

CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Automatically detects invasive carcinoma and quantifies ER-positive and negative tumor cells from whole-slide images (WSI) or selected tissue areas, supporting consistent and objective scoring.

Clinical performance highlights

• Exceptional diagnostic accuracy with high correlation to expert assessments
• Improved diagnostic consistency with reduced interobserver variability
• Accelerated workflow with up to 47% faster ER scoring

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Automatically detects invasive carcinoma and quantifies PR-positive and negative cells from whole-slide images (WSI) or selected tissue regions, enhancing diagnostic clarity and workflow.

Clinical performance highlights

• High diagnostic confidence with enhanced interobserver agreement
• Reliable reproducibility with near-perfect consistency
• Efficient workflow with approximately 12% faster scoring

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Accurately identifies invasive carcinoma and scores HER2 expression in alignment with CAP guidelines,  improving diagnostic reliability and workflow efficiency.

Clinical performance highlights

• Outstanding sensitivity and precision for confident HER2 classification
• Enhanced diagnostic consistency with increased interobserver concordance
• Objective support to identify challenging HER2-low and HER2-ultralow cases

CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Automatically detects invasive carcinoma and quantifies Ki67-positive and negative tumor cells from whole-slide images (WSI) or targeted image regions, improving diagnostic accuracy and workflow.

Clinical performance highlights

• High diagnostic accuracy with excellent correlation to expert visual scoring
• Enhanced diagnostic concordance through improved pathologist agreement
• Significant time savings, reducing scoring duration by up to 54%
• Reliable precision with automated hotspot detection for accurate proliferation assessment
  
  

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Supports the detection and quantification of metastases of breast cancer in lymph nodes from whole slide images.

Clinical performance highlights

• Showed excellent correlation with visual diagnosis
• Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

Automatically detects invasive carcinoma and delivers standardized, reproducible TPS scoring, enhancing diagnostic accuracy and efficiency. It assists pathologists in overcoming the challenges of subjective and time-consuming manual PD-L1 scoring in lung cancer.

Clinical performance highlights

• Excellent diagnostic accuracy with high correlation to expert visual assessments
• Enhanced consistency through improved pathologist concordance (Fleiss’ Kappa ~0.87)
• Significantly streamlined workflow, reducing analysis time by up to 46%
• Reliable and standardized scoring at critical clinical thresholds (e.g., 1% and 50%)

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Automatically identifies adenocarcinoma, streamlines the Gleason grading process, and directly addresses interobserver variability and subtle pattern detection challenges commonly faced by pathologists.

Clinical performance highlights

• Exceptional diagnostic accuracy with excellent correlation to expert grading
• Improved reproducibility and reduced interobserver variability
• Significantly faster Gleason scoring, saving up to 34% of analysis time

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Efficiently detects subtle perineural invasion (PNI) features, addressing the common diagnostic challenge of accurately and consistently identifying tumor involvement around nerves.

Clinical performance highlights

• High diagnostic confidence with excellent correlation to visual assessments
• Improved reproducibility, ensuring reliable identification of subtle PNI
• Enhanced workflow efficiency with scoring times reduced by up to 29%

CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Automatically detects Gleason Grade 4 Cribriform patterns in prostate biopsy whole slide images (WSI), addressing pathologists' challenges with subjective, time-consuming visual assessments, with the aim to reduce diagnostic variability and enhance workflow efficiency.

Clinical performance highlights

• Excellent diagnostic reliability, consistently aligning with expert visual assessments
• Improved reproducibility and reduced diagnostic variability
• Significantly reduced analysis time, improving workflow by up to 54%

CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Supports the detection of high-grade prostatic intraepithelial neoplasia (high-grade PIN) in whole slide images (WSI) of prostate tissue. 

Aiforia® Prostate Cancer HG-PIN is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

Identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for treatment decisions. This prognostic AI model was developed and validated in collaboration with the Mayo Clinic.

Clinical performance highlights

• Verified and validated in the Aiforia® Platform using whole slide images from eight independent hospitals and patient cohorts
• Improved risk stratification as compared to the American Society of Clinical Oncology staging

Aiforia® Colorectal Cancer QuantCRC is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Learn more

Supports the detection and quantification of metastases of colorectal cancer in lymph nodes from whole slide images. The AI model was developed in collaboration with the University of Bern.

Clinical performance highlights

• Showed excellent correlation with visual diagnosis
• Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Supports the detection and quantification of metastases of breast cancer, melanoma, and colorectal cancer in lymph nodes from whole slide images.

Clinical performance highlights: 

• Showed excellent correlation with visual diagnosis
• Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.